Chanelle Pharma, Ireland’s largest manufacturer of generic pharmaceuticals for human and animal health, has appointed Angelo Gatto as CEO.

Angelo brings 25 years of international experience in pharmaceuticals, in a career spanning animal health, human health and CDMO. He has held operational, commercial and management roles at Johnson & Johnson, Pfizer, Aenova Group, and most recently, Adragos Pharma. Having played a key role on Exponent’s advisory team at the time of its investment in Chanelle Pharma, he now joins the business to lead the next phase of its growth.

“I am very pleased to announce the appointment of Angelo Gatto as CEO of Chanelle Pharma, following a global search,” said chairman Carsten Hellmann. “Angelo brings relevant experience in all our business areas, and has demonstrated remarkable excellence throughout his entire career. I am confident in his ability to lead Chanelle Pharma through this exciting next chapter.”

Angelo said, “Chanelle Pharma has built an incredible brand with strong foundations and a unique positioning for ‘one-health’ which focuses on both human and animal health. I look forward to working closely with our team, leveraging strong capabilities to foster our emerging product pipeline.”

Chanelle Pharma employs more than 700 people in Ireland, the UK, Portugal and Jordan.  Headquartered in Loughrea, Ireland, Chanelle Pharma operates four manufacturing and five R&D. Its global supply chain and distribution network exports to over 80 countries. In February 2024, Chanelle Pharma was acquired by Exponent, a European private equity firm.